GlassScriptPhysician profile
Megan Rettew
NPI 1720867781
$3,624.89
in general payments reported to CMS, 2019-2025
21 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,678 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,611 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,611.00 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,158.63 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $553.37 | 2024-2025 | |
| Amgen INC. | $300.15 | 2024-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $287.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.03 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $221.09 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $140.70 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $140.32 | 2024-2025 | Rexulti |
| Medtronic, INC. | $95.29 | 2024-2025 | Symplicity G3, Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $58.25 | 2025 | |
| Glaxosmithkline, LLC. | $51.82 | 2024-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $49.34 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $45.78 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $40.63 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $39.81 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $33.71 | 2025 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.08 | 2025 | Caplyta |
| Recor Medical INC | $32.63 | 2025 | Paradise Ultrasound Renal Denervation System |
| Daiichi Sankyo INC. | $26.01 | 2025 | Injectafer |
| Lundbeck LLC | $19.49 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $16.16 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Rettew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.